Skip to content Skip to footer
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

14 articles published Follow:
Literature Reviews

Complete Guide to GenAI-enabled Literature Review for Life Sciences: MadeAi vs. Competitors

Thought Leadership12 February 2026152Views0Likes0Comments
Every professional in the life sciences knows the feeling: literature review is challenging, time-consuming, and above all, exhausting. This essential step in research can feel like a massive hurdle, slowing down innovation and consuming countless hours. Recognizing this frustration, MadeAi developed MadeAi-LR, a powerful GenAI-enabled solution designed to transform the literature review process. It provides the…

Read More

Literature Review

Literature Reviews: How AI is Revolutionizing Systematic Research

Thought Leadership4 February 2026100Views0Likes0Comments
In an era where scientific publications double every nine years and over 2.5 million new research papers are published each year, keeping your literature review up to date is nearly impossible. Enter the Living Literature Review, a significant shift that turns static research snapshots into continually evolving knowledge ecosystems. Why Traditional Literature Reviews Are Becoming…

Read More

Rare Disease

From Patient Voices to Actionable Insights: Why Social Media Listening Matters for Rare Disease Companies

Thought Leadership30 January 2026117Views0Likes0Comments
Understanding patient burden and unmet needs has always been essential in healthcare. But for rare diseases research, it is absolutely critical. When patient populations are small, heterogeneous, and often underserved, every insight carries weight. Yet traditional data sources—clinical trials, claims data, registries, and surveys—often fall short of capturing the lived reality of patients and caregivers…

Read More

FDA Literature Review

FDA Literature Review Requirements: Leveraging AI into Your Literature Review Strategy

Thought Leadership23 January 202669Views0Likes0Comments
Understanding FDA Literature Review Requirements The FDA requires literature reviews to ensure that regulatory decisions are based on solid scientific evidence. This isn't just about compiling papers; it's about systematically searching, appraising, and synthesizing published data to demonstrate safety, efficacy, and compliance. These requirements span multiple domains, from drug approvals to medical devices and health…

Read More

Literature Reviews

A Smarter Way to Adopt AI for Literature Reviews in Regulated Environments

Thought Leadership16 January 202683Views0Likes0Comments
Though many organizations see the value of AI in literature reviews and evidence generation, not all can adopt AI in the same way. Some teams are ready for a web-based SaaS solution. While others, especially large pharma and regulated enterprises, face internal AI policy barriers, data residency requirements, and IT constraints that make SaaS adoption difficult,…

Read More

MadeAi

MadeAi™ Unveils New Capabilities for GVD and JCA Reporting, Setting a New Benchmark for Life Science GenAI-Enabled Evidence Synthesis and Reporting

MadeAi Press Release10 November 202598Views0Likes0Comments
GLASGOW, SCOTLAND and CAMBRIDGE, MA, USA  November 10, 2025—At ISPOR Europe 2025 today, MadeAi™, the GenAI-powered evidence synthesis and report generation platform for life sciences, announced the launch of new capabilities designed to streamline and accelerate global value dossier (GVD) and Joint Clinical Assessment (JCA) submissions. With these advancements, MadeAi delivers the most comprehensive, AI-native…

Read More